BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 17565352)

  • 1. Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice.
    Sabatino DE; Mackenzie TC; Peranteau W; Edmonson S; Campagnoli C; Liu YL; Flake AW; High KA
    Mol Ther; 2007 Sep; 15(9):1677-85. PubMed ID: 17565352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of antigen-specific regulatory CD4+CD25+ T cells in tolerance induction after neonatal IP administration of AAV-hF.IX.
    Shi Y; Falahati R; Zhang J; Flebbe-Rehwaldt L; Gaensler KM
    Gene Ther; 2013 Oct; 20(10):987-96. PubMed ID: 23759700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B.
    Rogers GL; Martino AT; Zolotukhin I; Ertl HC; Herzog RW
    J Transl Med; 2014 Jan; 12():25. PubMed ID: 24460861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
    Wang L; Cao O; Swalm B; Dobrzynski E; Mingozzi F; Herzog RW
    Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.
    Cooper M; Nayak S; Hoffman BE; Terhorst C; Cao O; Herzog RW
    Hum Gene Ther; 2009 Jul; 20(7):767-76. PubMed ID: 19309290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
    Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
    Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
    Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
    Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscle as a target for supplementary factor IX gene transfer.
    Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW
    Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.
    Mingozzi F; Liu YL; Dobrzynski E; Kaufhold A; Liu JH; Wang Y; Arruda VR; High KA; Herzog RW
    J Clin Invest; 2003 May; 111(9):1347-56. PubMed ID: 12727926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector.
    Liu YL; Mingozzi F; Rodriguéz-Colôn SM; Joseph S; Dobrzynski E; Suzuki T; High KA; Herzog RW
    Hum Gene Ther; 2004 Aug; 15(8):783-92. PubMed ID: 15319035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functions of AAV-CMV-F.IX And AAV-EF1alpha-F.IX in gene therapy for hemophilia B.
    Wiwanitkit V
    Hum Gene Ther; 2007 Feb; 18(2):89-92. PubMed ID: 17266422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B.
    Cao O; Hoffman BE; Moghimi B; Nayak S; Cooper M; Zhou S; Ertl HC; High KA; Herzog RW
    Mol Ther; 2009 Oct; 17(10):1733-42. PubMed ID: 19603001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
    Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
    Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
    Cohn EF; Zhuo J; Kelly ME; Chao HJ
    J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.
    Manno CS; Pierce GF; Arruda VR; Glader B; Ragni M; Rasko JJ; Ozelo MC; Hoots K; Blatt P; Konkle B; Dake M; Kaye R; Razavi M; Zajko A; Zehnder J; Rustagi PK; Nakai H; Chew A; Leonard D; Wright JF; Lessard RR; Sommer JM; Tigges M; Sabatino D; Luk A; Jiang H; Mingozzi F; Couto L; Ertl HC; High KA; Kay MA
    Nat Med; 2006 Mar; 12(3):342-7. PubMed ID: 16474400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technology evaluation: AAV factor IX gene therapy, Avigen Inc.
    Fabb SA; Dickson JG
    Curr Opin Mol Ther; 2000 Oct; 2(5):601-6. PubMed ID: 11249763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
    George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
    Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
    Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
    Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
    Arruda VR; Schuettrumpf J; Herzog RW; Nichols TC; Robinson N; Lotfi Y; Mingozzi F; Xiao W; Couto LB; High KA
    Blood; 2004 Jan; 103(1):85-92. PubMed ID: 12969984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.